N/A
N=70
ARemind: A Personalized System to Remind for Adherence
Medication Adherence
Bottom Line
View on ClinicalTrials.gov: NCT01229722 ↗Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Adherence to Anti-retroviral Therapy — 0.69; 0.73; 0.62; .67 proportion adherence
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Beeper (Device); ARemind (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Dimagi Inc.
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adherence to Anti-retroviral Therapy |
0.69; 0.73; 0.62; .67; 0.5; .64 | — |
| PRIMARY Self-Report |
.93; .95; .95; .95; .93; .95 | — |
| PRIMARY Pill Count |
.59; .66; .62; .6; .58; .62 | — |
Summary
The main aim of this phase II proposal is to continue and complete development of a cellular phone-based system that assists patients with their medication adherence. Adherence reports will be developed with feedback from patients and providers. Software for patients to report their four day recall adherence through text messaging or short message service (SMS) or interactive voice response (IVR) will be built. An initial qualitative study will evaluate the adherence reports, 4-day adherence recalls, and inform the development of content for reminder text messages that could be resistant to user fatigue. A redesigned system will be tested through a 3-week longitudinal study of 15 patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). An intervention module will have an analytics engine to track adherence levels and personalize delivery of reminder messages. A clinic appointment module will perform patient appointment reminders. The final system with these modules will be tested through a 24-week efficacy study. A total of 115 patients and providers will be involved in the three user studies.
Eligibility Criteria
Inclusion Criteria
- Stable ART (no change of ART for 3 months)
- Greater than 18 years of age
- Self-report adherence < 85%
Exclusion Criteria
- HIV-infected patients not on ART
- Non-English speaking
- Dementia (via mini mental status exam)
- Incarceration
- Legally blind and./or deaf
- User of pillboxes
Data sourced from ClinicalTrials.gov (NCT01229722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.